Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib dose escalation with concurrent breast and regional nodal radiotherapy in breast cancer
NL-OMON44691Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of olaparib in breast cancer, sponsored by Netherlands Cancer Institute. Started Oct 2013; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON44691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44691.